Mengjie Xiao
Jinan, 250012, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Elevation of p53 sensitizes obese kidney to adriamycin-induced aberrant lipid homeostasis via repressing HNF4α-mediated FGF21 sensitivity.
Journal: Journal of advanced research
Published: April 12, 2024
Aberrant activation of p53-TRIB3 axis contributes to diabetic myocardial insulin resistance and sulforaphane protection.
Journal: Journal of advanced research
Published: March 28, 2024
SESN2-Mediated AKT/GSK-3β/NRF2 Activation to Ameliorate Adriamycin Cardiotoxicity in High-Fat Diet-Induced Obese Mice.
Journal: Antioxidants & redox signaling
Published: June 02, 2023
Integration of dietary nutrition and TRIB3 action into diabetes mellitus.
Journal: Nutrition reviews
Published: May 25, 2023
Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway.
Journal: Frontiers in pharmacology
Published: May 10, 2022
Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation.
Journal: Frontiers in pharmacology
Published: January 26, 2022
Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2.
Journal: Redox biology
Published: January 07, 2022
A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity.
Journal: Redox biology
Published: October 24, 2021
Regulatory role of endogenous and exogenous fibroblast growth factor 1 in the cardiovascular system and related diseases.
Journal: Pharmacological research
Published: November 29, 2020
Regulatory mechanisms of Sesn2 and its role in multi-organ diseases.
Journal: Pharmacological research
Published: September 01, 2020
NRF2-Related Epigenetic Modifications in Cardiac and Vascular Complications of Diabetes Mellitus.
Journal: Frontiers in endocrinology
Published: August 23, 2020
Last Updated: 09/26/2026